Fig. 2: Construction and validation of the RE score model in BCa. | npj Digital Medicine

Fig. 2: Construction and validation of the RE score model in BCa.

From: Integrative molecular–radiopathomic characterization of AIRE-driven immune subtypes in bladder cancer

Fig. 2

A Kaplan–Meier survival analysis revealed significantly worse prognosis in Cluster C2 compared to C1 (P < 0.001). B, C Immune cell infiltration analysis using ssGSEA, MCPcounter, and CIBERSORT showed higher levels of TIICs (e.g., CD4+, CD8+ T cells, macrophages) and immune activation in C2. D PCA-based RE score model divided TCGA-BCa patients into high and low RE score groups (n = 197 and n = 198, respectively); heatmap illustrates associations with clinical features. E GO analysis of low RE score signature genes revealed enrichment in T cell activation and intercellular adhesion; KEGG analysis showed ECM receptor interaction, TGF-β, and T cell receptor pathways. F Validation in GSE31684, GSE32894, GSE48075, and STPH datasets showed that high RE score samples had better OS (P < 0.05). G FPS validation in an independent STPH cohort confirmed better prognosis in high RE score samples. H Immunotherapy cohort analysis (IMvigor210, GSE78220, GSE176307) revealed lower OS and response rates in high RE score samples; combined low PD-L1 and high RE score predicted poor outcomes. I In the TCGA-PRAD cohort, patients with low TMB and low RE score had worse OS. Results are presented as mean ± SD. ns indicates P > 0.05;* indicates P < 0.05; ** indicates P < 0.01; *** indicates P < 0.001.

Back to article page